Modulating mechanism

Why investors backed neurology company Aptinyx’s $70M series B

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials from NYX-2925

Read the full 371 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE